Evaluation of GLR2007 for Advanced Solid Tumors

An Open-Label, Multicenter, Phase 1b/2 Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects With Advanced Solid Tumors

Evaluation of GLR2007 for Advanced Solid Tumors

Study Overview

• Status: Completed
• Conditions: Glioblastoma Multiforme; Non-small Cell Lung Cancer
• Intervention / Treatment: Drug: GLR2007

Detailed Description

An Open-Label, Multicenter, Phase 1b/2 Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects with Advanced Solid Tumors

• Study Type: Interventional
• Enrollment (Actual): 19
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • Indiana
    • Lafayette, Indiana, United States, 47905
      • USA002
  • Nebraska
    • Omaha, Nebraska, United States, 68130
      • USA005
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19111
      • USA001
  • Texas
    • Dallas, Texas, United States, 75230
      • USA004

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. For Part 1 (Dose Escalation): Participants with advanced solid tumors who are refractory or intolerant to therapies known to provide clinical benefit.

   1. For Part 1 (Dose Escalation): The participant must have histological or cytological evidence of cancer (a solid tumor) that is advanced and/or metastatic. Biopsy is allowed by protocol if no histology or cytology records are available.
   2. For Part 2 (Dose Expansion): The participant must have histological or cytological evidence of cancer that is advanced and/or metastatic.
2. For Part 1 (Dose Escalation): The participant has measurable or non-measurable disease.
3. For Part 2 (Dose Expansion): The participant has measurable disease.
4. The participant has given written informed consent prior to all study-specific procedures.
5. The participant has adequate hematologic, hepatic, and renal function.
6. The participant has discontinued all prior cancer therapies (including chemotherapy, immunotherapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for radiotherapy and non-myelosuppressive agents, prior to receiving GLR2007, and has recovered from the acute effects of therapy (treatment related toxicity resolved to ≤Grade 1) except for residual alopecia.
7. The participant is willing and able to make themselves available for the duration of the study and is willing and able to follow study procedures.
8. The participant meets contraceptive requirements.
9. The participant has an estimated life expectancy of ≥3 months.
10. The participant agrees to minimize ultraviolet exposure and sunlight for the duration of their study participation.
11. A diagnostic contrast-enhanced magnetic resonance imaging (MRI) of the brain must be performed within 28 days prior to registration. Contrast-enhanced computed tomography (CT) is acceptable if MRI is not possible.

Cohort-specific inclusion criteria Part 2 (Cohort A, NSCLC)

1. Histologically or cytologically confirmed NSCLC.
2. Participants must have received at least 1 line of standard therapy for metastatic disease, including platinum-based chemotherapy and an immune checkpoint inhibitor given together or as separate lines of therapy, unless participants are ineligible for or cannot tolerate such therapy.
3. Participants with anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), proto-oncogene tyrosine-protein kinase ROS (ROS1), v-Raf murine sarcoma viral oncogene homolog B (BRAF), and neurotrophic receptor tyrosine kinase 1 (NTRK) aberrations must have received therapy directed at their molecular aberration in order to enroll on this study.

Part 2 (Cohort B, Brain metastases of breast or NSCLC origin)

1. Histologically or cytologically confirmed NSCLC or breast cancer at primary site.
2. Participants with inoperable brain metastases (prior radiation therapy and/or stereotactic radiosurgery is allowed). A neurosurgical consult is at the discretion of the investigator.
3. Participants with brain metastases of NSCLC origin must have received at least 1 line of standard therapy for metastatic disease, including platinum-based chemotherapy and an immune checkpoint inhibitor given together or as separate lines of therapy, unless participants are ineligible for or cannot tolerate such therapy.
4. Participants with ALK, EGFR, ROS1, BRAF, and NTRK aberrations must have received therapy directed at their molecular aberration in order to enroll on this study.
5. Participants with brain metastases from breast cancer who have previously received CDK4/6 inhibitors.

Part 2 (Cohort C, GBM)

1. Histologically confirmed diagnosis of a recurrent primary World Health Organization Grade IV malignant glioblastoma. Participants with recurrent disease whose diagnostic pathology confirmed glioblastoma will not need re-biopsy. Participants with prior low-grade glioma or anaplastic glioma are eligible if histologic assessment demonstrates transformation to GBM.
2. First recurrence of GBM.
3. Candidate for surgical partial or gross-total resection.
4. Radiographic demonstration of disease progression by contrast-enhanced CT or MRI following prior therapy.
5. At least 2 weeks between prior surgical resection and adequate wound healing.
6. At least 12 weeks from prior radiotherapy unless there is either histopathologic confirmation of recurrent tumor or new enhancement on MRI outside of the treatment field.

Exclusion Criteria:

1. The participant has a personal history of any of the following conditions: major surgical resection involving the stomach or small bowel recurrent, unexplained or cardiac-related syncopal episodes within the last 6 months or ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation).
2. Any concurrent malignancies currently requiring treatment or for which treatment would be deemed necessary within 3 months of enrollment; prostate cancer with androgen deprivation therapy, basal cell cancer, and squamous cell cancers are allowed.
3. The participant is pregnant or lactating.
4. The participant is immunocompromised and known to be human immunodeficiency virus positive. The participant has an active bacterial, fungal, and/or known viral infection (for example, hepatitis B surface antigen or hepatitis C antibodies).

Cohort-specific exclusion criteria:

Part 2 (Cohort A, NSCLC): The participant has NSCLC with worsening symptoms within 14 days prior to receiving GLR2007.

Part 2 (Cohort B, Brain metastases of breast or NSCLC origin): The participant has CNS metastasis with worsening symptoms within 14 days prior to receiving GLR2007.

Part 2 (Cohort C, GBM): The participant has GBM with worsening symptoms within 14 days prior to receiving GLR2007.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part 1: Dose Escalation; Dose escalation cohorts are planned to determine the maximum tolerated dose or recommended phase 2 dose of GLR-2007, as well as expansion cohorts and a Phase 2 cohort.	Drug: GLR2007; Administered orally, once daily for 21 days followed by a 7-day treatment holiday.; Other Names: GLR2007-237FA
Experimental: Part 2: Dose Expansion - Cohort A; Participants who have received 2 or more second-line therapies, with at least 1 line of standard therapy, for their non-small cell lung cancer (NSCLC) will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.	Drug: GLR2007; Administered orally, once daily for 21 days followed by a 7-day treatment holiday.; Other Names: GLR2007-237FA
Experimental: Part 2: Dose Expansion - Cohort B; Participants who have received 2 or more second-line therapies, with at least 1 line of standard therapy, for their brain metastases of breast or NSCLC origin will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.	Drug: GLR2007; Administered orally, once daily for 21 days followed by a 7-day treatment holiday.; Other Names: GLR2007-237FA
Experimental: Part 2: Dose Expansion - Cohort C; Participants experiencing their first recurrence glioblastoma multiforme (GBM) will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.	Drug: GLR2007; Administered orally, once daily for 21 days followed by a 7-day treatment holiday.; Other Names: GLR2007-237FA

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Dose Escalation: Dose-limiting Toxicities	Up to 12 Months
Dose Escalation: Incidence And Severity Of Adverse Events, Including The Incidence Of Dose-limiting Toxicities Within The First Cycle	Up to 12 Months
Dose Expansion: Incidence And Severity Of Adverse Events	Up to 96 Weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose Escalation: Objective Response Rate	Defined by response evaluation criteria in solid tumors (RECIST) Version 1.1 (solid tumors) or by response assessment in neuro-oncology (RANO) (brain metastases and GBM).	8 Weeks
Dose Expansion: Objective Response Rate	Defined by RECIST Version 1.1 or by RANO as appropriate.	12, 24, 36, 48, 60, 72, 84, and 96 Weeks
Dose Escalation And Expansion: Maximum Observed Plasma Concentration After Single And Multiple Oral Dose Administrations		0, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours postdose
Dose Escalation And Expansion: Time At Which Maximum Plasma Concentration Is Observed And Apparent Half-life After Single And Multiple Oral Dose Administrations		0, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours postdose
Dose Escalation And Expansion: Area Under The Plasma Concentration-time Curve From 0 To Last Measurable Concentration And From 0 To Infinity After Single And Multiple Oral Dose Administrations		0, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours postdose
Dose Escalation And Expansion: Accumulation Ratio After Single And Multiple Oral Dose Administrations		0, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours postdose
Dose Escalation And Expansion: Steady-state Volume Of Distribution After Single And Multiple Oral Dose Administrations		0, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours postdose
Dose Escalation And Expansion: Clearance After Single And Multiple Oral Dose Administrations		0, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours postdose

Collaborators and Investigators

• Sponsor: Gan and Lee Pharmaceuticals, USA
• Investigators: Study Director: Kimberly Lazaroff, MSN, Gan and Lee Pharmaceuticals, USA Corp

Study record dates

Study Major Dates

• Study Start (Actual): July 15, 2020
• Primary Completion (Actual): July 29, 2022
• Study Completion (Actual): July 29, 2022

Study Registration Dates

• First Submitted: June 19, 2020
• First Submitted That Met QC Criteria: June 19, 2020
• First Posted (Actual): June 23, 2020

Study Record Updates

• Last Update Posted (Actual): December 23, 2022
• Last Update Submitted That Met QC Criteria: December 21, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: Breast Cancer; Glioblastoma Multiforme; Advanced Solid Tumors; Non-small Cell Lung Cancer; GLR2007
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms by Histologic Type; Neoplasms; Lung Diseases; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma
• Other Study ID Numbers: GLP-CDK-1009

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No